INTERCEPT PHARMACEUTICALS, INC. Insider Trading for January 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in INTERCEPT PHARMACEUTICALS, INC. for January 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 21.50 | 2,500 | 53,750 | 8,749 | |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 0.00 | 325 | 0 | 973 | |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Sell | S | 267.94 | 3,250 | 870,805 | 1,943 | 5.2 K to 1.9 K (-62.58 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 21.50 | 2,500 | 53,750 | 5,193 | 2.7 K to 5.2 K (+92.83 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 0.00 | 325 | 0 | 2,693 | 2.4 K to 2.7 K (+13.72 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 31.90 | 5,625 | 179,438 | 16,875 | |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 283.90 | 250 | 70,975 | 10,708 | 11 K to 10.7 K (-2.28 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 280.00 | 125 | 35,000 | 10,958 | 11.1 K to 11 K (-1.13 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 274.00 | 50 | 13,700 | 11,083 | 11.1 K to 11.1 K (-0.45 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 265.00 | 250 | 66,250 | 11,133 | 11.4 K to 11.1 K (-2.20 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 264.00 | 250 | 66,000 | 11,383 | 11.6 K to 11.4 K (-2.15 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 263.00 | 250 | 65,750 | 11,633 | 11.9 K to 11.6 K (-2.10 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 262.00 | 250 | 65,500 | 11,883 | 12.1 K to 11.9 K (-2.06 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 260.00 | 500 | 130,000 | 12,133 | 12.6 K to 12.1 K (-3.96 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 258.30 | 500 | 129,150 | 12,633 | 13.1 K to 12.6 K (-3.81 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 257.27 | 750 | 192,950 | 13,133 | 13.9 K to 13.1 K (-5.40 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 256.00 | 500 | 128,000 | 13,883 | 14.4 K to 13.9 K (-3.48 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 255.00 | 500 | 127,500 | 14,383 | 14.9 K to 14.4 K (-3.36 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 253.63 | 1,150 | 291,675 | 14,883 | 16 K to 14.9 K (-7.17 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 251.55 | 300 | 75,465 | 16,033 | 16.3 K to 16 K (-1.84 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 31.90 | 5,625 | 179,438 | 16,333 | 10.7 K to 16.3 K (+52.53 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 8.67 | 10,000 | 86,667 | 240,960 | |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Sell | S | 273.68 | 10,000 | 2,736,767 | 430,298 | 440.3 K to 430.3 K (-2.27 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 8.67 | 10,000 | 86,667 | 440,298 | 430.3 K to 440.3 K (+2.32 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 2.89 | 12,850 | 37,122 | 13,111 | |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 2.89 | 8,653 | 24,998 | 0 | |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Gift | G | 0.00 | 7,840 | 0 | 430,298 | 438.1 K to 430.3 K (-1.79 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 2.89 | 12,850 | 37,122 | 438,138 | 425.3 K to 438.1 K (+3.02 %) |
| Jan 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 2.89 | 8,653 | 24,998 | 425,288 | 416.6 K to 425.3 K (+2.08 %) |
| Jan 10 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 3,800 | 32,933 | 50,719 | |
| Jan 10 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 5,168 | 53,748 | 47,620 | |
| Jan 10 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 73.09 | 928 | 67,826 | 8,663 | 9.6 K to 8.7 K (-9.68 %) |
| Jan 10 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 71.56 | 4,000 | 286,239 | 9,591 | 13.6 K to 9.6 K (-29.43 %) |
| Jan 10 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 3,800 | 32,933 | 13,591 | 9.8 K to 13.6 K (+38.81 %) |
| Jan 10 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 5,168 | 53,748 | 9,791 | 4.6 K to 9.8 K (+111.79 %) |
| Jan 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 10.40 | 1,634 | 16,994 | 8,000 | |
| Jan 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 67.41 | 1,634 | 110,148 | 6,392 | 8 K to 6.4 K (-20.36 %) |
| Jan 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 10.40 | 1,634 | 16,994 | 8,026 | 6.4 K to 8 K (+25.56 %) |
| Jan 09 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Sell | S | 67.41 | 1,839 | 123,967 | 1,640 | 3.5 K to 1.6 K (-52.86 %) |
| Jan 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 1,623 | 0 | 12,980 | |
| Jan 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 1,623 | 0 | 4,623 | 3 K to 4.6 K (+54.10 %) |
| Jan 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,298 | 0 | 10,385 | |
| Jan 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,298 | 0 | 10,708 | 9.4 K to 10.7 K (+13.79 %) |
| Jan 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 0.00 | 4,868 | 0 | 38,942 | |
| Jan 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 0.00 | 4,868 | 0 | 416,635 | 411.8 K to 416.6 K (+1.18 %) |
| Jan 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 5,192 | |
| Jan 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 6,392 | 5.7 K to 6.4 K (+11.30 %) |